Objective To explore the value of tirofiban hydrochloride in patients with acute myocardial infarction ( AMI) by percutaneous coronary intervention ( PCI) . Methods Seventy-four patients with AMI were divided into observation group(n =42) and control group(n = 32) ,the patients in control group were treated with conventional therapy,based on this, the patients in observation group were treated with tirofiban hydrochloride. The bleeding events,left ventricular ejection fraction ( LVEF) , left ventricular end-diastolic volume index ( LVEDVI) , left ventricular end-systolic volume index ( LVESVI) and main adverse effect of heart were observed in two groups. Results There was no statistical difference in the rate of bleeding between two groups (P > 0. 05). The incidence rate of thrombocytopenia in observation group was lower than that in control group ( P < 0. 05). Compared with control group, LVEF, LVEDVI and LVESVI were improved obviously in observation group one month after operation(P <0.05). Three months after operation,there was no statistical difference in LVEF,LVEDVI and LVESVI between two groups (P > 0. 05 ). The incidence rate of main adverse effect of heart in observation group was lower than that in control group (P <0. 05) . Conclusion Tirofiban hydrochloride can effectively improved the heart function, prevent platelet aggregation , decrease the incidence rates of bleeding, thrombocytopenia and main adverse effect of heart in patients underwent PCI.%目的 探讨盐酸替罗非班在急性心肌梗死( AMI)患者经皮冠状动脉介入(PCI)治疗中的应用价值.方法 74例AMI患者分为观察组42例和对照组32例,对照组患者给予常规治疗,观察组在常规治疗的基础上给予盐酸替罗非班.观察2组患者出血事件、左心室射血分数(LVEF)、左心室舒张末期容积指数(LVEDVI)、左心室收缩末期容积指数(LVESVI)及主要心脏不良反应.结果 2组出血率比较差异无统计学意义(P＞0.05)；观察组血小板减少症发生率低于对照组(P＜0.05).术后1个月观察组LVEF、LVEDVI及LVESVI较对照组明显改善(P＜0.05)；术后3个月2组患者LVEF、LVEDVI及LVESVI比较差异无统计学意义(P＞0.05).观察组患者主要心脏不良反应事件发生率低于对照组(P＜0.05).结论 盐酸替罗非班可有效改善行PCI治疗患者的心功能,抗血小板聚集,减少出血、血小板减少症及主要心脏不良反应事件的发生.
展开▼
